Main Menu

F-Star Therapeutics, Inc.


Rigrodsky Law, P.A. is investigating F-Star Therapeutics, Inc. (“F-Star”) regarding possible breaches of fiduciary duties and other violations of law related to F-Star’s agreement to be acquired by invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited. Under the terms of the agreement, F-Star’s shareholders will receive $7.12 in cash for each share of F-Star common stock they own.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 11/24/2022

* Indicates a required field.

Back to Page